Imagine knowing if a treatment will work for you before you start taking it. Approximately 1 in 3 people who have Rheumatoid Arthritis (RA) who are prescribed a biologic (anti-TNF) therapy such as Humira, Enbrel, Remicade, Cimizia, Inflectra, Simponi or Simponi Aria will sufficiently respond to treatment. There is no tool currently available to predict which person will respond to these drugs. Scipher Medicine
aspires to change this with PrismRATM
, a new test that could improve how RA is treated. AOCBV is participating in this study to help change the way RA is treated.
Continue reading AOCBV is Particpating in the PrismRA Study for RA Biologic Therapy